Device Therapy in Patients with Heart Failure: Is Medication Use Optimized and Are We Targeting Those Patients Most Likely to Benefit?

Background: To determine what proportion of device-eligible patients with heart failure treated in a specialized clinic are on optimal guideline-directed medical therapy (GDMT) at the time of device referral and their benefit-risk status.

Methods: A cohort study was conducted of all patients seen between January 2013 and August 2024. We characterized GDMT by the modified Heart Function Collaboratory score at the time of device referral and grouped patients by Multicenter Automatic Defibrillator Implantation Trial-II (MADIT-ICD) benefit-risk score.

Exploring Reperfusion Following Endovascular Thrombectomy.

Background and Purpose- Cerebral perfusion in acute ischemic stroke patients is often assessed before endovascular thrombectomy (EVT), but rarely after. Perfusion data obtained following EVT may provide additional prognostic information. We developed a tool to quantitatively derive perfusion measurements from digital subtraction angiography (DSA) data and examined perfusion in patients following EVT.

Computed Tomographic Perfusion Predicts Poor Outcomes in a Randomized Trial of Endovascular Therapy.

Background And Purpose: In the ESCAPE trial (Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion with Emphasis on Minimizing CT to Recanalization Times), patients with large vessel occlusions and small infarct cores identified with computed tomography (CT)/CT angiography were randomized to endovascular therapy or standard of care. CT perfusion (CTP) was obtained in some cases but was not used to select patients. We tested the hypothesis that patients with penumbral CTP patterns have higher rates of good clinical outcome.

Penumbral Imaging-Based Thrombolysis with Tenecteplase Is Feasible up to 24 Hours after Symptom Onset.

Background And Purpose: Thrombolysis >4.5 hours after ischemic stroke onset is unproven. We assessed the feasibility of tenecteplase (TNK) treatment in patients with evidence of an ischemic penumbra 4.